Biomedicines,
Год журнала:
2025,
Номер
13(3), С. 720 - 720
Опубликована: Март 15, 2025
Sodium–glucose
cotransporter-2
inhibitors
(SGLT2i)
are
a
specific
class
of
drugs
originally
developed
for
treating
type
2
diabetes
mellitus.
Subsequently,
studies
demonstrated
that
their
action
was
not
limited
to
glycemic
control
but
could
also
have
positive
effects
on
other
outcomes,
particularly
at
the
cardiovascular
level.
Indeed,
due
diuretic
effect,
SGLT2i
improve
clinical
chronic
heart
failure
and
reduce
risk
rehospitalization.
In
addition,
reported
protective
effect
major
events
mortality.
More
recently,
it
has
been
suggested
prescription
after
an
acute
myocardial
infarction
may
possible
inflammation,
arrhythmias,
ventricular
remodeling.
Here,
we
reviewed
focused
in
patients
treated
with
percutaneous
coronary
intervention.
Cardiovascular Research,
Год журнала:
2024,
Номер
120(11), С. 1241 - 1252
Опубликована: Июль 1, 2024
After
myocardial
infarction
(MI),
patients
with
type
2
diabetes
have
an
increased
rate
of
adverse
outcomes,
compared
to
without.
Diabetes
confers
a
1.5-2-fold
increase
in
early
mortality
and,
importantly,
this
discrepancy
has
been
consistent
over
recent
decades,
despite
advances
treatment
and
overall
survival.
Certain
assumptions
emerged
explain
risk,
such
as
differences
infarct
size
or
coronary
artery
disease
severity.
Here,
we
re-evaluate
that
evidence
show
how
contemporary
analyses
using
state-of-the-art
characterization
tools
suggest
the
received
wisdom
tells
incomplete
story.
Simultaneously,
epidemiological
mechanistic
biological
data
additional
factors
relating
processes
diabetes-related
inflammation
might
play
prominent
role.
Inflammatory
after
MI
mediate
injury
repair
are
thus
potential
therapeutic
target.
Recent
studies
shown
affects
immune
cell
numbers
drives
changes
bone
marrow,
leading
pro-inflammatory
gene
expression
functional
suppression
healing
repair.
review
around
prognosis
MI,
emphasis
on
targeting
presents
unexplored,
yet
valuable
opportunities
improve
cardiovascular
outcomes
vulnerable
patient
group.
Journal of Cardiovascular Pharmacology and Therapeutics,
Год журнала:
2024,
Номер
29
Опубликована: Янв. 1, 2024
Introduction
Sodium-glucose
cotransporter-
2
(SGLT2)
inhibitors
have
become
a
cornerstone
in
heart
failure
(HF),
Type
diabetes
mellitus
(T2DM),
and
cardiovascular
disease
(CVD)
management.
In
the
current
retrospective
study,
we
aimed
to
assess
efficacy
safety
of
SGLT2
early
following
acute
myocardial
infarction
(AMI).
Methods
Patients
with
T2DM
hospitalized
for
AMI
2017-2020
were
divided
according
therapy
status
on
discharge
(with
vs
without
therapy).
Primary
outcome
was
defined
as
composite
hospitalizations
HF,
recurrent
AMI,
cerebrovascular
accident
(CVA).
Secondary
outcomes
included
any
cause,
total
cumulative
number
hospitalizations,
all-cause
mortality.
Results
A
69
patients
(mean
age
59.2
±
8.2
years)
discharged
compared
253
62.5
9.8)
no
inhibitors.
During
first
year
post-AMI,
4
(5.8%)
treatment
group
16
(6.3%)
control
CV
events
(p
=
1.0).
had
lower
rates
hospitalization
cause
(31.9%
47.8%,
P
0.02),
change
mortality
(0%
3.6%,
0.21).
After
multivariate
regression
analysis,
only
female
gender
associated
increased
risk
readmission,
mainly
due
urinary
tract
infections.
No
diabetic
ketoacidosis
(DKA)
or
limb
amputation
reported.
Conclusions
We
found
that
initiation
is
safe
decreases
cause.
Pharmacological Research,
Год журнала:
2022,
Номер
188, С. 106591 - 106591
Опубликована: Дек. 9, 2022
Atrial
fibrillation
(AF)
is
the
most
frequent
arrhythmia
and
associated
with
substantial
morbidity
mortality.
Pathophysiological
aspects
consist
in
activation
of
pro-fibrotic
signaling
Ca2+
handling
abnormalities
at
atrial
level.
Structural
electrical
remodeling
creates
a
substrate
for
AF
by
triggering
conduction
cardiac
arrhythmias.
The
care
patients
focuses
predominantly
on
anticoagulation,
symptoms
control
management
risk
factors
comorbidities.
goal
therapy
points
to
restore
sinus
rhythm,
re-establish
atrioventricular
synchrony
improve
contribution
stroke
volume.
New
layer
information
better
comprehend
pathophysiology,
identify
targets
novel
pharmacological
interventions
consists
epigenetic
phenomena
including,
among
others,
DNA
methylation,
histone
modifications
noncoding
RNAs.
Moreover,
benefits
sodium-glucose
cotransporter
2
inhibitors
(SGLT2i)
diabetic
non-diabetic
cardiovascular
as
well
emerging
evidence
ability
SGLT2i
modify
signature
diseases
provide
solid
background
investigate
possible
role
this
drug
class
onset
progression
AF.
In
review,
following
summary
pathophysiology
management,
mechanisms
potential
are
discussed.
Expert Opinion on Investigational Drugs,
Год журнала:
2023,
Номер
32(9), С. 839 - 847
Опубликована: Сен. 2, 2023
Introduction
Sodium
Glucose
co-Transporter
2
(SGLT2)
inhibitors
(also
known
as
'gliflozins')
represent
a
cornerstone
to
treat
diabetes
mellitus.
Moreover,
recent
randomized
clinical
trials
have
demonstrated
important
cardioprotective
effects
of
gliflozins,
independent
the
presence
diabetes.
Herein,
we
summarize
therapeutic
progress
in
cardiovascular
field
obtained
with
SGLT2
inhibitors.
Frontiers in Endocrinology,
Год журнала:
2022,
Номер
13
Опубликована: Дек. 15, 2022
Atherosclerosis
is
a
lipid-driven
chronic
inflammatory
disease
that
widespread
in
the
walls
of
large
and
medium-sized
arteries.
Its
pathogenesis
not
fully
understood.
The
currently
known
includes
activation
pro-inflammatory
signaling
pathways
body,
increased
oxidative
stress,
expression
cytokines/chemokines.
In
innate
immune
response,
vesicles
are
an
important
component
with
ability
to
promote
maturation
factors,
release
amounts
cytokines,
trigger
cascade
responses,
clear
pathogens
damaged
cells.
Studies
last
few
years
have
demonstrated
NLRP3
play
crucial
role
development
atherosclerosis
as
well
its
complications.
Several
studies
shown
binding
ligands
promotes
inflammasome
formation,
activates
caspase-1,
ultimately
production
IL-1β
IL-18.
IL-18
considered
be
two
most
prominent
cytokines
atherosclerosis.
SGLT2
inhibitors
novel
hypoglycemic
agents
also
significant
antiatherosclerotic
effects.
However,
their
exact
mechanism
yet
clear.
This
article
review
literature
on
effects
mechanisms
inflammasome,
focusing
antiatherosclerosis.
Life,
Год журнала:
2022,
Номер
12(12), С. 2062 - 2062
Опубликована: Дек. 8, 2022
(1)
Background:
Sodium-glucose
co-transporter-2
(SGLT-2)
inhibitors
constitute
a
novel
drug
class
with
remarkable
cardiovascular
benefits
for
patients
chronic
heart
failure
(HF).
Recently,
this
has
been
utilized
in
acute
HF
as
an
additional
treatment
option
to
classic
diuretics,
which
remain
the
cornerstone
of
treatment.
(2)
Methods:
We
attempted
identify
those
pathophysiologic
mechanisms
targeted
by
SGLT-2
inhibitors,
could
be
benefit
HF.
then
conducted
comprehensive
review
literature
within
PubMed
database
order
relevant
studies,
both
randomized
controlled
trials
(RCTs)
and
observational
assessing
safety
efficacy
(3)
Results:
induce
significant
osmotic
diuresis
natriuresis,
decrease
interstitial
fluid
volume
blood
pressure,
improve
left
ventricular
(LV)
function,
ameliorate
LV
remodeling
prevent
atrial
arrhythmia
occurrence,
that
seem
beneficial
However,
currently
available
including
six
RCTs
two
real-world
provide
conflicting
results
concerning
true
“hard”
surrogate
endpoints.
(4)
Conclusions:
Current
evidence
appears
insufficient
substantiate
use
Further
are
required
shed
more
light
on
issue.
